Survival statistics for soft tissue sarcoma
Survival statistics for soft tissue sarcoma are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person’s chances of survival.
There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for soft tissue sarcoma and what they mean to you.
Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer but who share similar characteristics (such as age and sex).
In Canada, the 5-year relative survival for soft tissue sarcoma is 65%. This means that, on average, people diagnosed with soft tissue sarcoma are 65% as likely to live for at least 5 years after their diagnosis compared to people in the general population.
Survival statistics are not reported in Canada for each type of soft tissue sarcoma.
Survival by stage
Survival varies with each stage of soft tissue sarcoma. Generally, the earlier soft tissue sarcoma is diagnosed and treated, the better the outcome.
There are no specific Canadian statistics available for the different stages of soft tissue sarcoma. The following information comes from a variety of sources. It includes statistics from other countries that are likely to have similar outcomes as in Canada.
|Stage||5-year relative survival|
localized – cancer is only in one area of the body
regional – cancer has grown into nearby areas around where it started
metastatic (distant) – cancer has spread to other parts of the body
Questions about survival
Talk to your doctor about your prognosis. A prognosis depends on many factors, including:
- your health history
- the type of cancer
- the grade and stage
- where the cancer started in the body
- the treatments chosen
- how the cancer responds to treatment
Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.
Together we can reduce the burden of cancer
Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.